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Review Article
Charcot neuroarthropathy: pathogenesis, 
diagnosis and medical management 
Abstract
Charcot neuroarthropathy (CN) is a progressive degenerative 
arthropathy which rarely complicates diabetes mellitus. Most 
commonly, though not exclusively affecting the foot, it seems to 
be determined by the interaction of neuropathy, osteopaenia and 
proinflammatory cytokines on a calcified peripheral vasculature 
that maintains its ability to vasodilate despite widespread 
arteriosclerosis. Although often unrecalled, this arthropathy is 
probably triggered by trauma. Diagnosis is essentially clinical, 
given the paucity and non-specificity of radiological and 
biochemical findings at the acute stage. CN should be considered 
in the differential diagnosis of any diabetic patient presenting 
with a warm swollen lower extremity. Bone turnover markers, 
magnetic resonance imaging and radioisotope scanning may be 
useful diagnostic aids. Offloading is essential and improves limb 
survival. There is considerable interest, though limited data, on 
the benefits of bisphosphonates and calcitonin. The possible 
roles of ultrasound and radiotherapy need to be assessed in 
larger trials. Failure to institute corrective measures at an early 
stage results in a foot that is prone to deformity, ulceration, 
amputation and loss of function. It is hoped that a better 
understanding of the aetiopathogenesis at a cytokine level will 
allow the targeting of new effective agents.
Introduction
First reported in 1831 by the American physician John 
Kearsley Mitchell as secondary to tuberculosis induced 
spinal damage,1 denervation-induced joint destruction was 
described by the French neurologist Jean-Martin Charcot in 
1868 as a complication of tertiary syphilis.2 This degenerative 
neuropathic arthropathy was first associated with diabetes in 
1936.3 Indeed, diabetes is thought to be the commonest cause 
of CN in the developed world,4,5 although it may also complicate 
other diseases associated with peripheral neuropathy such as 
leprosy, syringomyelia, following traumatic denervation of a 
limb, and as a complication of alcohol abuse. With a reported 
incidence of around 0.1-0.5%,6-8 CN in diabetes almost always, 
though not exclusively, involves the foot. The midfoot or ankle 
joints are the most commonly affected joints. Involvement of 
the knee,9 hip,10 spine11 and wrist12 has also been reported. CN 
may develop in up to 16% of patients with diabetic neuropathy.13 
Both type 1 (T1DM) and type 2 diabetes (T2DM) patients appear 
to be equally at risk, although the former seem to present at 
a slightly earlier age.14 There is no sex predilection. Bilateral 
involvement may occur in up to 30%.4 Affected individuals 
generally present in the fourth or fifth decades of life, several 
years after the onset of diabetes.6,15 CN has been associated with 
premature mortality.16
Pathogenesis
Although the pathogenesis of acute Charcot foot remains 
unclear, neuropathy and inflammation are key features. A case 
series of 101 subjects with CN confirmed the presence of distal 
sensory neuropathy in all patients.6 Charcot himself proposed 
the so called ‘French theory’,2 wherein the joint deformity 
was attributed to damaged central nervous system centres 
that control bone and joint nutrition. Volkman and Virchow 
proposed the ‘German theory,’17,18 which suggested that multiple 
subclinical traumata in a denervated joint were the initial 
precipitating factor. 
It is postulated that minor trauma may trigger an 
inflammatory cascade through a complex pathway.19 The 
precipitating event is unrecalled in around two thirds of affected 
patients.4 CN has also been noted to follow local surgery, 
including revascularisation20 and orthopaedic procedures.21 
Trauma may lead to microfracture, sublaxation or dislocation. 
Abnormal joint loading is potentially further exacerbated by 
the neuropathy, such that a partial or complete lack of pain 
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leads to continued weight bearing and further joint damage. 
Interestingly, both neuropathy and diabetes are associated 
with osteopaenia, the link being stronger with T1DM.22,23 
Osteopaenia seems to carry a higher risk of microfracture 
compared to dislocation.24 However, there is no evidence so far 
for a difference in the presentation of CN between T1DM and 
T2DM. In a study on a small group of patients presenting with a 
hot swollen foot, Rawesh et al. demonstrated that reduced bone 
mineral density in the lower limb led to subsequent development 
of CN compared to patients with a higher bone mineral density 
at baseline.25 It is generally accepted that neuropathy impairs 
healing after an incidental traumatic fracture. The altered 
integrity of ligaments, possibly compromised in the acute phase 
by motor neuropathy,26,27 may account for a predilection for the 
involvement of joints dependent on ligamentous mechanical 
stability, such as the midtarsal joint.28 Limited mobility of the 
first metatarsophalangeal joint and plantar fascia dysfunction 
has been associated with mid-foot CN,31 although it is unclear 
whether these features precede or follow the onset of the joint 
damage.29 Patients with acute CN have been found to have 
higher plantar pressures in the metatarsophalangeal joints 
when compared to patients with distal sensorimotor neuropathy 
or neuropathic ulceration.30 It is postulated that the forefoot 
acts as a lever and causes collapse of the midfoot, which is 
the commonest site of involvement. Electron microscopy of 
the Achilles tendon has shown an increased packing density 
of collagen fibrils, decreased fibrillar diameter and abnormal 
fibril morphology.31 These changes may lead to shortening of 
tendons. The abnormal collagen may predispose to CN in these 
patients.31,32
Histological examination of surgical specimens revealed 
that osteoclasts significantly outnumber osteoblasts in Charcot 
reactive bone. These osteoclasts showed immunoreactivity 
for interleukin 1, interleukin 6 and tumour necrosis factor 
alpha (TNF-α).33 The inflammatory cascade is thought to be 
triggered by proinflammatory cytokines, principally TNF-α and 
interleukin 1 beta, which in turn trigger increased expression 
of the nuclear transcription factor-kappa B (NF-κB). This 
transcription factor plays an important part in bone dissolution 
by favouring osteoclast activation. An intermediate step in 
the activation of NF-κB may involve an increased expression 
of a specific transmembrane protein receptor activator called 
receptor activator of NF-κB ligand (RANKL).34,35 RANKL and 
TNF-α appear to be mutually enhancing, such that a vicious 
cycle is established.36 Osteoprotegerin, a glycoprotein member 
of the tumour necrosis factor family, acts as a decoy receptor 
for RANKL, effectively inactivating it when production is 
excessive. It is postulated that a coordinated synthesis of 
RANKL and osteoprotegerin is crucial in bone remodelling, 
allowing an appropriate balance between bone formation 
and resorption.37 The RANKL-NF-κB pathway is implicated 
in the aetiopathogenesis of arterial wall smooth muscle 
calcification.38,39 Vascular calcification (Monckeberg’s sclerosis) 
is a prominent feature of diabetic neuropathy and Charcot foot, 
being present in up to 90% patients with the latter pathology.6 
It is thought that, in the absence of neuropathy, pain-
induced joint immobilisation halts the above inflammatory 
osteolytic process by reducing local blood flow.40 Baseline blood 
flow is increased in neuropathic feet as a result of a reduced 
peripheral vascular resistance and sympathetic denervation, but 
does not increase in response to warming. Charcot feet retain 
the capacity to increase vascular flow further, exacerbating the 
inflammatory process. 
In summary, it is possible that CN is the result of a 
precipitating insult on a susceptible individual. The relative 
contribution of the above factors may vary between T1DM and 
T2DM, and from one patient to another.41 
Clinical presentation and diagnosis
CN of the foot may be anatomically classified into five 
different types, based on the joints involved5 (Table 1). A 
different classification system42  (Table 2) divides CN into 
forefoot, midfoot and hindfoot CN. Midfoot43 or type II CN is the 
commonest variety. Acute CN of the ankle, hindfoot or midfoot 
heals at a slower rate than forefoot arthropathy.44  
A high index of suspicion is essential, particularly in 
the acute stage. The situation is further complicated by the 
absence of a clear working definition of this disease entity.45 
Not uncommonly, acute CN is misdiagnosed as cellulitis, 
osteomyelitis or an inflammatory arthropathy.6 Deep vein 
thrombosis should also be considered in the differential 
diagnosis. Avascular necrosis of the navicular bone is less 
common, but may show similar features to Charcot foot.46 
The diagnosis of acute CN remains predominantly clinical. 
Investigations largely help to distinguish the condition from 
others that cause pain and swelling of the foot.
Table 1: Anatomical classification 
of Charcot neuroarthropathy (CN) of the foot5
Type of CN Joint/s involved 
I  metatarsophalangeal, interphalangeal
II  tarso-metatarsal 
III  tarsal
IV  sub-talar
V  calcaneum 
Table 2: Classification of Charcot 
neuroarthropathy (CN) of the foot42
Type of CN Joint/s involved
forefoot metatarsophalangeal, interphalangeal, 
midfoot tarso-metatarsal, tarsal
hindfoot  ankle, calcaneum
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The affected individual often presents with a swollen 
painful foot or lower extremity. Although patients have severe 
peripheral neuropathy, pain is the commonest complaint, 
followed by discomfort.15,47 On examination, the foot is noted to 
be warm, with a temperature difference of over 2ºC compared 
to the contralateral side. There may be a clinical joint effusion, 
usually non-inflammatory or haemorrhagic, which may 
contain mononuclear cells.48 The pedal pulse on the affected 
side may be bounding compared to the contralateral lower 
limb.49 A significant proportion of patients with acute CN have 
a concomitant ulcer, further complicating the diagnosis, and 
raising the possibility of osteomyelitis. The acute phase may 
take several months to subside, and is followed by a painless 
foot, which does not show any temperature difference to the 
other side. Continued weight bearing results in a deformed 
foot that is prone to ulceration and amputation (Figures 1 and 
2). Moreover, the disease process may become reactivated by 
further trauma, making the differentiation from osteomyelitis 
more difficult.7 Handheld infrared dermal thermometers may 
be used to assess skin temperature differences,50 thus allowing 
monitoring of healing (associated with ‘foot cooling’) and 
recurrence (associated with ‘foot warming’). Laser doppler 
shows an increased cutaneous blood flow in CN, differentiating 
from peripheral neuropathy.51 
Radiographs, largely useful for their anatomical information, 
may be normal or show only subtle changes at an early stage. 
Once established, bone and joint destruction, fragmentation 
and remodelling are evident (Figure 3).52 Any associated 
osteomyelitis cannot be distinguished in the presence of severe 
bone and joint damage.53 Early magnetic resonance imaging 
(MRI) appearances are non-specific, and can also be seen 
in bone-stressing phenomenon, acute osteomyelitis, reflex 
sympathetic dystrophy or sepsis.54 There is significant overlap 
of signal intensity from the marrow for infection and oedema. 
Established CN is characterised by a low T1 signal from the joint 
and a low T2 signal from the marrow.55 Rapid onset CN with a 
high bone turnover rate and marked oedema is associated with 
a high T2 signal, mimicking osteomyelitis.56  Osteonecrosis 
and recent surgery may also give this picture,57 with the signal 
remaining high for 3 to 6 months after surgery. The greater 
the signal from the marrow on T2 weighted images, the more 
likely the bone is infected.58 Gadolinium treatment does not 
help differentiating between oedema and infections.59 MRI 
is useful for preoperative assessment and to monitor disease 
progression. Positron emission tomography (PET) can be used 
in the evaluation of CN patients with metal implants that would 
compromise the accuracy of MRI. Moreover, PET was also 
shown to distinguish between osteomyelitis and CN.60,61 
Three-phase 99mTc bisphosphonate bone scans are positive 
in all three phases, reflecting the increased bone turnover 
characteristic of CN (Figure 4). It is a very sensitive but non-
discriminatory test.58 A four phased bone scan (with a delayed 
image at 24 hours) is more specific to detect woven bone but 
does not distinguish CN from severe degenerative changes, 
fractures and tumours.53 A 111In-labelled leucocyte scan shows 
increased activity at the site of an infection, but does not usually 
accumulate where there is new bone formation in the absence 
of infection.53 However, such a scan may be positive with a 
recent-onset, rapidly advancing CN, due to the accumulation 
of leucocytes at fracture sites.62 This can be differentiated 
by complementary marrow scanning using Tc-nanocolloid 
alongside a 111In-labelled leucocyte scan.63 Congruence of both 
scans (both positive in the same area) indicates absence of 
infection, and points to CN. 53,62 
Figure 1: Foot deformity characteristic of established 
Charcot foot
Figure 2: Foot deformity characteristic of Charcot 
neuroarthropathy
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Occasionally, an increased C-reactive protein may be 
observed in acute CN.64 A very high erythrocyte sedimentation 
rate favours infection over CN, but is still non-specific.65 
Levels of bone specific alkaline phosphatase (a bone formation 
marker) and urinary deoxypyridinoline (a bone resorption 
marker) were found to be increased in acute CN compared to 
non-Charcot diabetic subjects, reflecting ongoing bone turnover 
and remodelling.66  Gough et al. found an increase in the bone 
resorption marker called pyridinoline cross-linked carboxy-
terminal telopeptide domain of type 1 collagen in acute CN. 
In contrast, levels of a bone formation marker called carboxy-
terminal propeptide of type 1 collagen were not increased.67 
Jirkovska et al not only confirmed an increase in plasma levels of 
pyridinoline cross-linked carboxy-terminal telopeptide domain 
of type 1 collagen in acute CN, but also directly correlated it with 
calcaneal bone density.68 Levels of cross-linked N telopeptides of 
type 1 collagen, a urinary marker of bone resorption, were found 
to be elevated in CN patients in a separate study.69 
In conclusion, diagnosis of CN, and in particular its 
differentiation from osteomyelitis remains difficult. The latter is 
particularly challenging in the presence of an ulcer. Some cases 
currently diagnosed as having osteomyelitis (particularly of the 
forefoot) may in fact be cases of CN.45     
Medical management
CN may be defined as a medical emergency, since failure 
to act quickly can lead to irreversible consequences.70 Once 
established, surgery may be necessary to remove bone 
deformities and reduce disability. Techniques include 
arthrodesis, exostectomies, reconstruction and Achilles 
tendon lengthening.58 Two studies investigating any benefits 
of ultrasound are limited by small samples and produced 
conflicting results.71,72 Given the non-specific nature of early 
presentation, it may be appropriate to treat the diabetic patient 
presenting with a warm swollen foot with antibiotics if an 
infection cannot be excluded.73 
Immobilisation 
Diabetic patients with acute ankle CN have been shown 
to have a better limb survival if they were treated with a non-
weight-bearing protective device, compared to patients who 
continued to bear weight.74 While the use of crutches or other 
assistive modalities may allow complete non-weight bearing 
and are acceptable forms of treatment, three-point gait may 
increase the pressure on the contralateral limb, predisposing 
it to repetitive stress, ulceration or neuropathic fracture.75 
Better alternatives include the use of a total contact cast (TCC) 
(made of plaster of Paris or fibreglass), Charcot restraint 
orthotic walker, a Scotchcast boot (made of Deltalite plaster), 
or pneumatic walking braces.15, 52, 76 Ambulation in a TCC was 
shown to result in a mean healing time of 86 days, with the 
most rapid healing occurring in forefoot CN.44 Armstrong and 
colleagues assessed the efficacy of serial TCC in 55 patients 
with acute Charcot foot until quiescence.15 These patients were 
allowed unprotected weight bearing using a removable cast 
walker when the temperature difference between the affected 
foot and the contralateral healthy foot was less than 1ºC for two 
consecutive weeks. Prescription footwear was allowed when the 
temperature equilibrated within 1ºC for one month. On average, 
patients’ feet became quiescent after around 4 months (range 4-
56 weeks). Patients could progress to permanent footwear after 
just over 6 months, although some required treatment for up to 
12 months. A study by McCrory et al.77 also assessed the role of 
Figure 3: Radiograph showing bone and joint deformities 
in Charcot neuroarthropathy of the ankle joint
Figure 4: Radioisotope scan showing increased ankle  
joint and foot uptake in the delayed phase in Charcot 
neuroarthropathy
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casting and foot temperature monitoring in acute CN, observing 
that radiographic healing began by 3-6 months, and that this 
is correlated with the time the foot began to ‘cool.’ Both studies 
confirmed the need for prolonged immobilisation, and that 
clinical indicators are required to ascertain the total duration 
of avoidance of weight bearing. TCCs need to be changed at 
least every 1 to 2 weeks to adjust to limb volume changes as 
the oedema decreases.78 There are as yet no published studies 
assessing the Scotchcast boot in acute Charcot foot. 
Bisphosphonates
There is as yet no pharmacological agent licensed for use 
in acute Charcot foot. A number of clinical trials assessing 
bisphosphonates in CN suggest clinical benefit. However, 
they are limited by the small number of participating patients. 
Bisphosphonates are synthetic analogues of inorganic 
pyrophosphate that decrease bone resorption by inhibiting 
the recruitment and activity of osteoclasts, while stimulating 
osteoblastic activity.79 Bisphosphonates may shorten the 
lifespan of osteoclasts and provide pain relief through effects 
on prostaglandin E2 and other nociceptive substances.80 
They have also been implicated to interfere with the release 
of neuropeptides and neuromodulators from afferent nerve 
endings.81,82 
In 1994, Selby et al. studied the effect of pamidronate on 6 
patients with CN.83 These subjects received an initial infusion 
of 60mg followed by a 30mg infusion fortnightly over 12 weeks. 
Patients’ symptoms and foot temperatures showed a significant 
improvement. Alkaline phosphatase levels fell by about 25% by 
the end of the study. Jude et al. carried a randomised double-
blind clinical trial on 39 diabetic patients with active CN, who 
were assigned placebo (normal saline) treatment or a 90mg 
single intravenous infusion of pamidronate. 47 All patients were 
instructed to immobilise the foot and avoid weight bearing. Both 
groups had a significant reduction of temperature at 2 weeks. 
The pamidronate group had a further reduction at 4 weeks, 
but there was no significant difference when comparing to the 
placebo group. All throughout the study, the pamidronate group 
had a significant reduction in symptoms compared to the placebo 
group. Both fasting plasma bone-specific alkaline phosphatase (a 
bone formation marker) and second-void early morning urinary 
deoxypyridinoline (a bone resorption marker, reported as a 
ratio with respect to urinary creatinine) showed a significant 
reduction in the pamidronate treated group compared to the 
placebo group. The first effect was seen around 4 weeks, and 
remained until 12-24 weeks. Levels returned towards baseline 
levels 6-12 months after the infusion. Anderson et al.84 reported 
significantly greater reductions in temperature (measured after 
48 hours and 2 weeks) and alkaline phosphatase (measured 
after 2 weeks) among CN patients treated with intravenous 
pamidronate compared to standard care alone. However, this 
study was not randomised, and there was bias in the treatment 
strategy. 
An Italian group studied the effect of the oral bisphophonate 
Alendronate (70 mg once a week) on 20 patients with acute 
painful CN.85 11 patients were randomised to treatment with the 
bisphosphonate but all received a TCC for the first 2 months and 
a pneumatic walker for the next 4 months, followed by the use 
of special shoes. Alendronate treated patients had a significant 
reduction of symptoms, a reduction in the levels of the bone 
resorption markers hydroxyproline and carboxy-terminal 
telopeptide of type 1 collagen, and an improvement in the bone 
mineral density of the foot.
 
Calcitonin
Secreted by the C-cells of the thyroid, calcitonin directly 
affects osteoclasts and interacts with the RANKL pathway.86 
In a recent study, 32 patients were randomised to receive a 
combination of intranasal calcitonin (200IU/day) and calcium 
supplementation (100mg/day) or calcium supplementation 
alone.87 Disease activity improved in both groups but there 
was a significant reduction in bone turnover markers in the 
calcitonin treated group. In a follow-up study involving 36 acute 
CN subjects,88 calcitonin treated patients had significantly faster 
healing compared to controls.
Conclusion
The diagnosis of acute CN requires a high index of suspicion. 
Larger trials would allow a better elucidation of the benefits, 
if any, of bisphosphonates and calcitonin in the acute setting. 
A better understanding of the underlying aetiopathogenesis, 
particularly of RANKL and osteoprotegerin, may allow 
the targeting of new treatment strategies, such as TNF-α 
antagonists, corticosteroids and nonsteroidal anti-inflammatory 
agents. Relative risks and benefits would need to be carefully 
weighed however, especially in those with ulceration of the skin 
or other risk of infection. In the meantime, immediate institution 
of effective offloading remains crucial. 
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